Gene Variation Hikes Odds of PTSD
The odds for developing post-traumatic stress disorder (PTSD) appear to be influenced by at least two genes that produce serotonin, the brain chemical that at low levels is often linked to depression.
UCLA scientists believe genetics explain why some persons succumb to post-traumatic stress disorder (PTSD) while others who suffered the same ordeal, do not.
Researchers have linked two serotonin producing genes to a higher risk of developing PTSD.
In the study, published in the online edition in the Journal of Affective Disorders, authors believe the role of heredity is so strong that future exploration of the genetic link may result in new ways of screening for and treating the disorder.
“People can develop post-traumatic stress disorder after surviving a life-threatening ordeal like war, rape or a natural disaster,” said lead author Dr. Armen Goenjian. “If confirmed, our findings could eventually lead to new ways to screen people at risk for PTSD and target specific medicines for preventing and treating the disorder.”
PTSD can arise following child abuse, terrorist attacks, sexual or physical assault, major accidents, natural disasters or exposure to war or combat. Symptoms include flashbacks, feeling emotionally numb or hyper-alert to danger, and avoiding situations that remind one of the original trauma.
Goenjian and his colleagues extracted the DNA of 200 adults from several generations of 12 extended families who suffered PTSD symptoms after surviving the devastating 1988 earthquake in Armenia.
In studying the families’ genes, the researchers found that persons who possessed specific variants of two genes were more likely to develop PTSD symptoms. Called TPH1 and TPH2, these genes control the production of serotonin, which helps to regulate mood, sleep and alertness — all of which are disrupted in PTSD.
“We suspect that the gene variants produce less serotonin, predisposing these family members to PTSD after exposure to violence or disaster,” said Goenjian. “Our next step will be to try and replicate the findings in a larger, more heterogeneous population.”
PTSD affects about 7 percent of Americans, with the disorder becoming a pressing health issue for a large percentage of war veterans returning from Iraq and Afghanistan. The UCLA team’s discovery could be used to help screen persons who may be at risk for developing PTSD.
“A diagnostic tool based upon TPH1 and TPH2 could enable military leaders to identify soldiers who are at higher risk of developing PTSD, and reassign their combat duties accordingly,” observed Goenjian.
“Our findings may also help scientists uncover alternative treatments for the disorder, such as gene therapy or new drugs that regulate the chemicals responsible for PTSD symptoms.”
According to Goenjian, the advantages of pinpointing genes connected with PTSD symptoms are far-reaching.
Researchers believe the findings will help neuroscientists classify the disorder based on brain biology instead of clinical observation. Psychiatrists currently rely on a trial and error approach to identify the best medication for controlling an individual patient’s symptoms.
Serotonin is a common target of mental health pharmaceuticals. Popular antidepressants known as SSRIs, or selective serotonin reuptake inhibitors, prolong the effect of serotonin in the brain by slowing its absorption by brain cells.
Recently, physicians are expanding prescription of SSRIs to treat psychiatric disease beyond depression, including PTSD and obsessive compulsive disorder.
Nauert PhD, R. (2012). Gene Variation Hikes Odds of PTSD. Psych Central. Retrieved on November 29, 2015, from http://psychcentral.com/news/2012/04/03/gene-variation-hikes-odds-of-ptsd/36863.html